Brazil Contraceptive Devices Market Size and Share

Brazil Contraceptive Devices Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
View Global Report

Brazil Contraceptive Devices Market Analysis by Mordor Intelligence

Brazil contraceptive devices market reached USD 512.64 million in 2025 and is forecast to achieve USD 689.36 million by 2030, advancing at a 6.38% CAGR. This trajectory reflects a policy environment that prioritizes domestic manufacturing, streamlined regulation, and primary-care expansion, all of which collectively widen method availability and spur technological upgrades. Rapid growth in e-commerce and direct-to-consumer channels strengthens privacy and price transparency, encouraging uptake among digitally active users. Heightened concern around sexually transmitted infections (STIs) sustains barrier-method demand, while government promotion of long-acting reversible contraceptives (LARCs) stimulates implant and IUD adoption. Material innovation focused on hypoallergenic and biodegradable options differentiates brands and aligns with Brazil’s rising environmental consciousness. Competitive positioning hinges on local production capacity, regulatory know-how, and the ability to pair digital engagement with clinician outreach.

Key Report Takeaways

  • By type, condoms led with 43.56% of Brazil contraceptive devices market share in 2024, whereas subdermal implants are set to expand at a 7.46% CAGR to 2030. 
  • By gender, female-oriented devices commanded 68.98% share of the Brazil contraceptive devices market size in 2024; male devices exhibit the highest projected CAGR at 8.25% through 2030. 
  • By material, latex held 79.35% share of the Brazil contraceptive devices market in 2024, and non-latex alternatives are growing at 8.40% CAGR. 
  • By distribution channel, retail pharmacies accounted for 51.23% of the Brazil contraceptive devices market size in 2024, whereas e-commerce and direct sales record a 9.34% CAGR through 2030.

Segment Analysis

By Type: Condoms Sustain Scale While Implants Accelerate

Condoms contributed 43.56% to the Brazil contraceptive devices market in 2024, supported by broad retail coverage and dual-protection messaging. Subdermal implants, while accounting for a smaller base, are on track for a 7.46% CAGR through 2030 as public clinics scale LARC programs. The Brazil contraceptive devices market size for implants is projected to grow steadily as domestic factories, financed under Nova Indústria Brasil, ramp up output. Condom vendors emphasize non-latex SKUs and antiviral lubricants to command premium shelf placement, whereas implant producers invest in provider training to boost insertion competencies across family-health teams.

Supply-chain volatility for copper complicates IUD production, yet localized assembly mitigates part of the pricing pressure. Vaginal rings gain niche appeal among health-conscious urban women seeking routine-free hormonal delivery. Diaphragms, cervical caps, and sponges remain niche because they require fitting or carry lower efficacy perceptions. Emerging “other devices,” including stimuli-responsive hydrogels, signal future avenues for reversible male and female contraception, though commercial impact lies beyond the current forecast horizon.

Market Segment Share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Get Detailed Market Forecasts at the Most Granular Levels
Download PDF

By Gender: Female Dominance Meets Rising Male Engagement

Female-focused products held 68.98% share in 2024, but male devices are positioned for an 8.25% CAGR as societal attitudes evolve toward shared responsibility. A push for dual-method use means condom demand coexists with hormonal and LARC adoption, rather than replacing it. Promotional campaigns now feature couple-based narratives, encouraging joint decision-making at clinic visits. Retailers report that multipacks sized for month-long use appeal to budget-sensitive male buyers; meanwhile, telehealth platforms experiment with mail-order vasectomy consultations, expanding the Brazil contraceptive devices industry reach.

Female device growth stems from expanding implant and IUD programs financed by state and municipal authorities. Manufacturers embed QR codes on packaging that link users to removal service locators, reducing anxiety around reversibility. As more men participate in contraceptive conversations, brands offering discreet male options, such as soon-to-launch reversible gels, stand to diversify revenue streams in the Brazil contraceptive devices market.

Market Segment share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Get Detailed Market Forecasts at the Most Granular Levels
Download PDF

By Material: Latex Dominates but Non-Latex Options Grow

Latex still delivers 79.35% of unit sales in 2024 because of favorable cost and manufacturing scale. Nonetheless non-latex alternatives advance at 8.40% CAGR, responding to allergy concerns and eco-impact scrutiny. The Brazil contraceptive devices market share for non-latex condoms remains low in unit terms, yet revenue contribution rises because of premium pricing. Polyurethane and polyisoprene brands highlight enhanced heat transfer and oil-based lubricant compatibility, positioning them for consumers valuing comfort and environmental claims.

Domestic producers invest in biodegradable wrappers and plant-based rubber sourcing to align with corporate ESG goals. Research into zinc-based IUDs seeks to offset copper price shocks while maintaining efficacy. Start-ups explore natural fiber diaphragms treated with antimicrobial coatings, aiming for environmental differentiation. As hospital procurement criteria evolve to include sustainability metrics, suppliers offering green credentials may secure priority in public tenders, reinforcing the shift within the Brazil contraceptive devices market size dynamics.

By Distribution Channel: Digital Platforms Disrupt Traditional Models

Retail pharmacies maintained 51.23% share in 2024 through professional guidance and widespread presence. Yet e-commerce and direct sales are accelerating at 9.34% CAGR, fueled by privacy, price comparison, and ANVISA’s e-labelling reforms. The Brazil contraceptive devices market size for online channels is projected to climb steadily as consumers increasingly opt for home delivery subscriptions timed with menstrual cycles or prescription refills. Influencer-curated bundles and same-day logistics enhance convenience, edging share away from brick-and-mortar formats.

Public health facilities concentrate on implants and IUDs that rely on clinician insertion, while retail chains dominate short-acting methods. Hospital pharmacies manage higher-cost hormonal rings and emergency contraception. NGOs distribute condoms and fertility awareness tools in remote communities, often using mobile clinics. Cross-channel strategies emerge: pharmacy chains launch online storefronts and integrate electronic prescriptions, and digital-first brands open pop-up kiosks during festivals to boost visibility and trust. This omnichannel interplay underpins consumer choice diversity within the Brazil contraceptive devices market.

market segment share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Get Detailed Market Forecasts at the Most Granular Levels
Download PDF

Geography Analysis

Brazil’s contraceptive landscape displays marked regional contrasts. The Southeast, led by São Paulo, benefits from mature healthcare infrastructure, capturing a sizable portion of implant and IUD demand. Public hospitals there report stock-out rates below 5%, supporting uninterrupted LARC programs. Higher household incomes translate into above-average uptake of non-latex condoms and hormonal rings, reinforcing premium market tiers within the Brazil contraceptive devices market.

In the North and Northeast, primary-care units record lower IUD availability and elevated adolescent pregnancy indicators. The Ministry of Health channels Family Health Strategy funding toward these zones, prioritizing provider training and device supply. NGO partnerships deploy mobile health units that leverage QR-based ordering to bypass logistical hurdles, fostering incremental increases in implant use. E-commerce adoption lags urban centers yet gains traction via smartphone penetration and cashless payment expansion.

The South registers the highest STI screening coverage, propelling consistent condom distribution. Local authorities integrate digital awareness campaigns during regional festivals, pairing QR codes with free condom samples. The Central-West combines agricultural prosperity with patchy clinic density, prompting a hybrid model where private telemedicine platforms coordinate prescription delivery. Across all regions, inflationary pressures influence brand choice, with consumers shifting between premium and value segments depending on real wage dynamics. Regional tailoring of product mix, pricing, and promotional channels is therefore essential to capture the full potential of the Brazil contraceptive devices market.

Competitive Landscape

Competition remains moderate, with a cluster of multinationals and agile domestic firms shaping the Brazil contraceptive devices market. Bayer leads the implant category through its Mirena franchise and leverages in-country manufacturing upgrades to comply with Nova Indústria Brasil localization targets. Q2 2024 results note implant revenue gains attributed to higher unit volumes and selective pricing. Ansell and LifeStyles Healthcare dominate condoms, pushing thin non-latex variants and antiviral coatings that cater to STI concerns.

Local specialist Hypera Pharma scales production of latex condoms and injectables, benefitting from BRL-denominated cost bases that hedge currency volatility. DKT International collaborates with community health programs to expand social-marketing reach, offering subsidized pricing in low-income municipalities. Start-ups experiment with biodegradable materials and male contraceptive prototypes, banking on ANVISA’s streamlined pathways to accelerate approval. Intellectual-property barriers remain modest, so differentiation hinges on brand equity, clinician trust, and omnichannel distribution strength.

Strategic moves in 2024-2025 emphasize vertical integration and digital engagement. Multinationals forge supply agreements with leading e-commerce marketplaces to guarantee next-day delivery, while domestic firms pilot WhatsApp-based refill reminders. Several providers invest in carbon-neutral packaging plants, aligning with procurement criteria that now weigh ESG metrics. Joint ventures between material-science companies and contraceptive brands explore plant-based rubber sources, signaling future competitive levers within the Brazil contraceptive devices industry.

Brazil Contraceptive Devices Industry Leaders

  1. Bayer AG

  2. Reckitt Benckiser Group plc

  3. Ansell Ltd

  4. Hypera Pharma S.A.

  5. CooperSurgical Inc.

  6. *Disclaimer: Major Players sorted in no particular order
Brazil Contraceptive Devices Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • June 2024: Ministry of Health initiates national Carnival campaign promoting condom use under the slogan “Carnival, respect and protection #MustHave”.
  • February 2024: Ministry of Health launches booklet on sexual education as a transformation policy.

Table of Contents for Brazil Contraceptive Devices Industry Report

1. Introduction

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Government Initiatives and Rising Awareness for Contraceptive Devices
    • 4.2.2 Rising Burden of Sexually Transmitted Infections (STIs)
    • 4.2.3 Growing Rate of Unplanned Adolescent Pregnancies
    • 4.2.4 ANVISA 2024-25 e-labelling & Reprocessing Rules Easing Market Entry
    • 4.2.5 Rising Initiatives for Long- Acting Reversible Contraceptives (LARCs)
    • 4.2.6 Technological Advancements and Emerging Demand for Eco-friendly/biodegradable Barrier Materials
  • 4.3 Market Restraints
    • 4.3.1 Side-effects & Discomfort Concerns with Device/Hormonal Methods
    • 4.3.2 Cultural Resistance & Misinformation Around LARCs
    • 4.3.3 Copper Price Volatility Disrupting IUD Supply Chain
    • 4.3.4 Low Reimbursement Incentives for Private OB-GYN Counselling
  • 4.4 Value / Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technology Outlook
  • 4.7 Porter’s Five Forces Analysis
    • 4.7.1 Bargaining Power of Suppliers
    • 4.7.2 Bargaining Power of Buyers
    • 4.7.3 Threat of New Entrants
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Intensity of Competitive Rivalry

5. Market Size and Growth Forecasts (Value-USD)

  • 5.1 By Type
    • 5.1.1 Condoms
    • 5.1.2 Diaphragms and Cervical Caps
    • 5.1.3 Vaginal Sponges
    • 5.1.4 Vaginal Rings
    • 5.1.5 Intra-Uterine Devices (IUD)
    • 5.1.6 Subdermal Implants
    • 5.1.7 Spermicidal Devices
    • 5.1.8 Other Devices
  • 5.2 By Gender
    • 5.2.1 Male
    • 5.2.2 Female
  • 5.3 By Material
    • 5.3.1 Latex
    • 5.3.2 Non-latex
  • 5.4 By Distribution Channel
    • 5.4.1 Public Health System
    • 5.4.2 Hospital Pharmacies
    • 5.4.3 Retail Pharmacies & Drugstores
    • 5.4.4 E-commerce & Direct Sales
    • 5.4.5 Family-planning Clinics & NGO Programs

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
    • 6.3.1 LifeStyles Healthcare
    • 6.3.2 Ansell Ltd
    • 6.3.3 Bayer AG
    • 6.3.4 Church & Dwight Co., Inc.
    • 6.3.5 Reckitt Benckiser Group plc
    • 6.3.6 Cooper Surgical Inc.
    • 6.3.7 Veru Inc.
    • 6.3.8 Merck & Co.
    • 6.3.9 Organon & Co.
    • 6.3.10 Hypera Pharma S.A.
    • 6.3.11 DKT International
    • 6.3.12 Skyn
    • 6.3.13 Linepharma International
    • 6.3.14 Mithra Pharmacueticals
    • 6.3.15 Cupid Ltd
    • 6.3.16 Okamoto Industries Inc.
    • 6.3.17 Gedeon Richter Plc

7. Market Opportunities and Future Outlook

  • 7.1 White-Space and Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Research Methodology Framework and Report Scope

Market Definitions and Key Coverage

Our study defines Brazil's contraceptive devices market as the annual sales value of barrier, long-acting reversible, and permanent birth-control devices that are cleared by ANVISA and dispensed through retail, hospital, and e-commerce channels. Included are condoms, diaphragms, cervical caps, contraceptive sponges, vaginal rings, hormonal and copper IUDs, and sub-dermal implants.

Scope exclusion: Contraceptive drugs, fertility-tracking apps, and emergency contraception pills lie outside our device-only scope.

Segmentation Overview

  • By Type
    • Condoms
    • Diaphragms and Cervical Caps
    • Vaginal Sponges
    • Vaginal Rings
    • Intra-Uterine Devices (IUD)
    • Subdermal Implants
    • Spermicidal Devices
    • Other Devices
  • By Gender
    • Male
    • Female
  • By Material
    • Latex
    • Non-latex
  • By Distribution Channel
    • Public Health System
    • Hospital Pharmacies
    • Retail Pharmacies & Drugstores
    • E-commerce & Direct Sales
    • Family-planning Clinics & NGO Programs

Detailed Research Methodology and Data Validation

Primary Research

Telephone interviews with gynecologists in Sao Paulo, SUS family-planning officers in the Northeast, and procurement managers of leading pharmacy chains helped verify unit uptake, distribution mark-ups, and the pace at which LARCs substitute condoms. Follow-up surveys with urban millennials and rural community-health agents bridged gaps on clandestine channels and brand stickiness.

Desk Research

Mordor analysts first mapped Brazil's demand pool using public health datasets such as SINASC live-birth files, PNDS family-planning surveys, and ANVISA device registration logs, which clarify prevalence, usage mix, and regulatory flow. We then layered import value trends from COMEX STAT, demographic updates from IBGE, STI incidence from the Ministry of Health, and procurement bulletins from the Unified Health System. Trade association white papers (e.g., FEBRASGO), academic journals indexed in SciELO, and company 10-K filings provided pricing clues and product mix ratios. Paid databases including D&B Hoovers and Dow Jones Factiva supplemented manufacturer revenue splits and recent tender values. This list is illustrative; many additional open and subscription sources were screened to validate signals.

Market-Sizing & Forecasting

A top-down prevalence-to-treated-cohort build-up linked reproductive-age female population, contraceptive prevalence rate, and device mix to 2024 volumes, which are then priced with weighted average selling prices obtained from channel checks. Results are corroborated once through selective bottom-up supplier roll-ups and shipment audits to fine-tune under-reported rural volumes. Key model drivers include adolescent fertility rate, public-sector LARC procurement budget, latex import price index, e-commerce share of OTC health, and condom breakage recall events. A multivariate regression with ARIMA error correction projects each driver through 2030; scenario bands derived from expert consensus tackle policy or currency shocks. Data blanks (e.g., informal street sales) are back-cast using urban penetration proxies before inclusion.

Data Validation & Update Cycle

Outputs undergo three-layer review: peer analyst cross-checks, senior mentor audit, and a variance screen against external device shipment moves. We refresh every twelve months, re-opening the model sooner if ANVISA issues major recalls or SUS revises tender volumes; the file you receive reflects the latest pass.

Why Mordor's Brazil Contraceptive Devices Baseline Commands Reliability

Published estimates often diverge because firms slice the market differently, apply contrasting ASP ladders, or refresh at uneven intervals.

Key gap drivers here include: a) exclusion of contraceptive drugs in our scope, b) Mordor anchors to SUS tender realizations while others assume retail-only mark-ups, and c) our annual model refresh versus multi-year static baselines elsewhere.

Benchmark comparison

Market Size Anonymized source Primary gap driver
USD 512.6 mn (2025) Mordor Intelligence -
USD 323.3 mn (2024) Regional Consultancy A Narrow urban sample; omits public LARC roll-outs
USD 1,295.2 mn (2024) Global Consultancy B Combines devices with hormonal drugs; ASP inflated with private-clinic tariffs

The comparison shows that when scope, price ladders, and update cadence are aligned with ground realities, Mordor delivers a balanced, transparent baseline that decision-makers can trace back to clear variables and repeatable steps.

Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

1. What is the current value of the Brazil contraceptive devices market?

The market stands at USD 512.64 million in 2025 and is projected to hit USD 689.36 million by 2030.

2. Which type holds the largest Brazil contraceptive devices market share?

Condoms lead with 43.56% share in 2024, driven by dual-protection messaging.

3. What segment is growing fastest within the market?

Subdermal implants post the highest CAGR at 7.46% through 2030, reflecting government support for LARCs.

4. How are digital channels influencing sales?

E-commerce and direct sales grow at 9.34% CAGR, supported by ANVISA e-labelling rules that simplify online dispensing.

5. Which material segment is gaining momentum?

Non-latex options register an 8.40% CAGR as consumers seek hypoallergenic and eco-friendly alternatives.

6. What is the main regulatory development shaping market entry?

ANVISA’s 2024-25 reforms permit electronic labelling and extended import timelines, cutting approval delays for new devices.

Page last updated on:

Brazil Contraceptive Devices Report Snapshots